ESR1 and neoplasm: While it has been demonstrated that glyceollins are novel antiestrogens, an alternant mechanism has been suggested, whereby glyceollins target ER‐independent pathways regulating tumor cell proliferation and/or survival of triple negative breast cancer cells [23].